SCYX-7158 (AN5568): CNS Exposure Predicted from First-in-Human Clinical Studies Indicates a Single Oral Dose Treatment is Possible for Sterile Cures of Stage 2 Human African Trypanosomiasis

Development of tetrahydroisoquinoline analogues: Towards a treatment for Human African Trypanosomiasis

This research describes the exploration of a new scaffold with the potential to be developed in to a

Cerebrospinal fluid biomarkers for stage determination and treatment outcome evaluation in patients affected by Human African trypanosomiasis

Human African trypanosomiasis (HAT) is a neglected parasitic disease affecting rural communities in

The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis

New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice

Optimization of pyrazolopyridine derivatives for the treatment of human African trypanosomiasis

Despite recent advances in the development of therapeutics for human African trypanosomiasis, new tr

Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis

ABSTRACT The screening of a focused library identified FTY720 (Fingolimod;